<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> cell lines expressing bcl-2 with <z:chebi fb="6" ids="45863">taxol</z:chebi> induces bcl-2 phosphorylation and programmed cell <z:hpo ids='HP_0011420'>death</z:hpo>, whereas treatment of bcl-2-negative <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> cells with <z:chebi fb="6" ids="45863">taxol</z:chebi> does not induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in <z:chebi fb="6" ids="45863">taxol</z:chebi>-treated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>These findings support the use of the anticancer drug <z:chebi fb="6" ids="45863">taxol</z:chebi> for the treatment of bcl-2-positive <z:hpo ids='HP_0012125'>prostate cancers</z:hpo> and other bcl-2-positive <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, such as follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>